Sage Therapeutics Appoints Jessica Federer to Board of Directors
March 16 2023 - 5:30AM
Business Wire
Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical
company leading the way to create a world with better brain health,
today announced the appointment of Jessica Federer to the company’s
Board of Directors.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230316005117/en/
Jessica Federer (Photo: Business
Wire)
“We are thrilled to have Jessica join our Board of Directors.
Jessica is a champion for patients and has a track record of
innovation in data and digital transformation which will be a key
future growth driver for the industry,” said Barry Greene, Chief
Executive Officer at Sage Therapeutics. “Jessica’s innate
curiosity, commitment to challenging convention, and patient-first
mindset are consistent with the critical values that define our
leaders. Her unique expertise in data and digitalization at the
intersection of policy and science will help us continue to scale
our commercial growth ambitions.”
Ms. Federer is a managing partner at Supernode Ventures where
she is working to address a critical gap in innovation by
accelerating change through investment in women’s health and health
technology companies as early as possible in pre-seed, seed, and
Series A rounds. She was the first Chief Digital Officer for the
Bayer AG group, as well as the first woman to hold that role in the
industry. During her tenure, Ms. Federer united the company’s
global digital strategy and investments to accelerate growth. She
also held leadership positions in regulatory affairs, market
access, communications, and public affairs during her almost 10
years with Bayer AG.
Ms. Federer has served on the United Nations International
Telecommunications Union (UN-ITU) advisory board, as well as
participated in engagements with the World Economic Forum, and is
considered a thought leader in digital health. She began her public
health career as an analyst at the Agency for Healthcare Research
and Quality in the U.S. Department of Health and Human Services.
She earned a Bachelor of Science from the George Washington
University and a Master of Public Health from Yale University.
“I’m honored to join the Sage Board of Directors at such an
incredibly exciting time. Sage has led the way in maternal mental
health care, an area of great need and one that is particularly
important to me. I’m looking forward to supporting the company’s
goal of redefining how we think about and treat a wide range of
brain health conditions. I see the vast potential for data and
digital strategies in the brain health area,” said Ms. Federer.
About Sage Therapeutics
Sage Therapeutics is a biopharmaceutical company fearlessly
leading the way to create a world with better brain health. Our
mission is to pioneer solutions to deliver life-changing brain
health medicines, so every person can thrive. For more information,
please visit http://www.sagerx.com.
Forward-Looking Statements
Various statements in this release concern Sage's future
expectations, plans and prospects, including without limitation:
our views and expectations regarding our goals, opportunity, plans,
mission and potential for our programs, strategies and business.
These statements constitute forward-looking statements as that term
is defined in the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are neither promises nor
guarantees of future performance, and are subject to a variety of
risks and uncertainties, many of which are beyond our control,
which could cause actual results to differ materially from those
contemplated in these forward-looking statements, including the
risks that: the FDA may ultimately decide that the design or
results of our completed, ongoing and planned clinical trials for
any of our product candidates, even if positive, are not sufficient
for regulatory approval in the indications that are the focus of
our efforts; other decisions or actions of the FDA or other
regulatory agencies may affect the regulatory paths for our product
candidates or the initiation, timing, design, size, progress and
cost of clinical trials and our ability to proceed with further
development; success in our earlier clinical trials or non-clinical
studies may not be repeated or observed in ongoing or future
studies, and ongoing and future clinical and non-clinical results
may not meet their primary or key secondary endpoints or support
further development; we may encounter adverse results or adverse
events in use of our products or product candidates that negatively
impact further development, our ability to obtain regulatory
approval or our commercialization plans or that require additional
nonclinical and clinical work which may not yield positive results;
the unmet need for additional treatment options, the impact of our
planned strategies, our ability to change treatment paradigms, and
the potential for our current or future products, may be
significantly smaller than we expect; we may encounter technical
and other unexpected hurdles in the development and manufacture of
our product candidates or commercialization of any of our products
which may delay our timing or change our plans or increase our
costs; as well as those risks more fully discussed in the section
entitled "Risk Factors" in our most recent Quarterly Report on Form
10-Q, as well as discussions of potential risks, uncertainties, and
other important factors in our subsequent filings with the
Securities and Exchange Commission. In addition, any
forward-looking statements represent our views only as of today and
should not be relied upon as representing our views as of any
subsequent date. We explicitly disclaim any obligation to update
any forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230316005117/en/
Investors Helen Rubinstein 315-382-3979
helen.rubinstein@sagerx.com
Media Matthew Henson 917-930-7147
matthew.henson@sagerx.com
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Sep 2023 to Sep 2024